Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Takeda
Vedanta Biosciences, Inc.
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Mayo Clinic
NGM Biopharmaceuticals, Inc
Aprea Therapeutics
Hutchmed
MacroGenics
BioNTech SE
Fukushima Medical University
NextCure, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
Basilea Pharmaceutica
Genmab
Nektar Therapeutics
Incyte Corporation
Silverback Therapeutics
Incyte Corporation
Novartis
National Cancer Institute (NCI)
Asan Medical Center
Western Regional Medical Center
Northwestern University
Generic Devices Consulting, Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company